Product: Cox2 Antibody
Catalog: AF7003
Description: Rabbit polyclonal antibody to Cox2
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog
Mol.Wt.: 80kDa, 70 kDa; 69kD(Calculated).
Uniprot: P35354
RRID: AB_2835311

View similar products>>

   Size Price Inventory
 50ul $250 In stock
 100ul $350 In stock
 200ul $450 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(88%), Dog(100%)
Cox2 Antibody detects endogenous levels of total Cox2.
Cite Format: Affinity Biosciences Cat# AF7003, RRID:AB_2835311.
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.


COX 2; COX-2; COX2; Cyclooxygenase 2; Cyclooxygenase 2b; Cyclooxygenase; Cyclooxygenase-2; Cyclooxygenase2; EC; fj02a10; Glucocorticoid-regulated inflammatory cyclooxygenase; Glucocorticoid-regulated inflammatory Prostaglandin G/H synthase; GRIPGHS; hCox 2; Macrophage activation-associated marker protein P71/73; OTTHUMP00000033524; PES-2; PGG/HS; PGH synthase 2; PGH2_HUMAN; PGHS 2; PGHS-2; PGHS2; PHS 2; PHS II; PHS2; Prostaglandin endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase); Prostaglandin endoperoxide synthase 2; Prostaglandin G/H synthase 2; Prostaglandin G/H synthase 2 precursor; Prostaglandin G/H synthase and cyclooxygenase; Prostaglandin G/H synthase; Prostaglandin H2 synthase 2; prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase); Prostaglandin-endoperoxide synthase 2; PTGS2; ptgs2a; TIS10; TIS10 protein; unp1239; wu:fj02a10;


COX-2 Mediates the formation of prostaglandins from arachidonate. May have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity. Homodimer. Belongs to the prostaglandin G/H synthase family.



Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P35354 As Substrate

Site PTM Type Enzyme
N53 N-Glycosylation
Y120 Phosphorylation P07948 (LYN)
N130 N-Glycosylation
K155 Ubiquitination
K166 Ubiquitination
K346 Ubiquitination
N396 N-Glycosylation
K445 Ubiquitination
Y446 Phosphorylation P06241 (FYN)
N580 N-Glycosylation

Research Backgrounds


Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. In cancer cells, PTGS2 is a key step in the production of prostaglandin E2 (PGE2), which plays important roles in modulating motility, proliferation and resistance to apoptosis. During neuroinflammation, plays a role in neuronal secretion of specialized preresolving mediators (SPMs), especially 15-R-lipoxin A4, that regulates phagocytic microglia (By similarity).


S-nitrosylation by NOS2 (iNOS) activates enzyme activity. S-nitrosylation may take place on different Cys residues in addition to Cys-526.

Acetylated at Ser-565 by SPHK1. During neuroinflammation, acetylation by SPHK1 promotes neuronal secretion of specialized preresolving mediators (SPMs), especially 15-R-lipoxin A4, which results in an increase of phagocytic microglia.

Subcellular Location:

Microsome membrane>Peripheral membrane protein. Endoplasmic reticulum membrane>Peripheral membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:



Belongs to the prostaglandin G/H synthase family.

Research Fields

· Environmental Information Processing > Signal transduction > NF-kappa B signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Parasitic > Leishmaniasis.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Chemical carcinogenesis.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Small cell lung cancer.   (View pathway)

· Metabolism > Lipid metabolism > Arachidonic acid metabolism.

· Metabolism > Global and overview maps > Metabolic pathways.

· Organismal Systems > Immune system > IL-17 signaling pathway.   (View pathway)

· Organismal Systems > Nervous system > Retrograde endocannabinoid signaling.   (View pathway)

· Organismal Systems > Nervous system > Serotonergic synapse.

· Organismal Systems > Endocrine system > Ovarian steroidogenesis.

· Organismal Systems > Endocrine system > Oxytocin signaling pathway.

· Organismal Systems > Endocrine system > Regulation of lipolysis in adipocytes.


1). Efficient Therapy of Inflammatory Bowel Disease (IBD) with Highly Specific and Durable Targeted Ta2C Modified with Chondroitin Sulfate (TACS). Advanced Materials, 2023 (PubMed: 37224059) [IF=29.4]

Application: WB    Species: Mouse    Sample: RAW264.7 cells

Figure 7.TACS relieves inflammation and restores intestinal barrier function. B)WB analysis of COX-2 and iNOS proteins expression in RAW264.7 cells with different treatments.

2). Microbiota-microglia crosstalk between Blautia producta and neuroinflammation of Parkinson's disease: A bench-to-bedside translational approach. Brain, behavior, and immunity, 2024 (PubMed: 38211635) [IF=15.1]

Application: IHC    Species: Mouse    Sample:

Fig. 3. Administration of B. producta inhibited microglia activation and neuroinflammation in PD mice. (A) Representative immunohistochemistry images of Iba-1 and COX-2 among Con, MPTP and MPTP + B. producta groups, Magnification: 200 ×, Scale bars: 100 μm. (B) Representative Western blot images of Iba-1 among three groups. (C) Quantitative analysis of Iba-1level; the ratio of Iba-1/β-actin in the Con group was used as a reference value. Error bars indicate the SEM, **P < 0.01 vs. Con group, #P < 0.05 vs. MPTP group.

3). Combination therapy of PKCζ and COX-2 inhibitors synergistically suppress melanoma metastasis. Journal of Experimental & Clinical Cancer Research, 2017 (PubMed: 28865485) [IF=11.3]

Application: WB    Species: mouse    Sample: B16F10

Fig. 5 The expression of p-PKCζ, p-cofilin and COX-2 after combined treatment of J-4 and Celecoxib. (a) Western blotting images of p-cofilin and COX-2 in B16-F10 cells with various treatments for 24 h. (b) Western blotting images of p-cofilin and COX-2 in A375 cells with various treatments for 24 h. (c) Relative mRNA level of PKCζ and COX-2 determined via RT-PCR. (d) The expression of EMT markers, E-Cadherin and Vimentin, and MMP-2/MMP-9 was affected in B16-F10 and A375 cells after various treatments for 24 h. J-4: 25 μM; Celecoxib: 25 μM. * P < 0.05; ** P < 0.01

4). Ganoderma lucidum polysaccharide modulates gut microbiota and immune cell function to inhibit inflammation and tumorigenesis in colon. Carbohydrate Polymers, 2021 (PubMed: 34119183) [IF=11.2]

5). Suppression of the SLC7A11/glutathione axis causes ferroptosis and apoptosis and alters the mitogen-activated protein kinase pathway in nasopharyngeal carcinoma. International journal of biological macromolecules, 2024 (PubMed: 37951442) [IF=8.2]

6). Restoring perturbed oxylipins with Danqi Tongmai Tablet attenuates acute myocardial infarction. Phytomedicine, 2021 (PubMed: 34252738) [IF=7.9]

7). Compound Danshen Dripping Pill inhibits doxorubicin or isoproterenol-induced cardiotoxicity. Biomedicine & Pharmacotherapy, 2021 (PubMed: 34311530) [IF=7.5]

8). Luteolin attenuates imiquimod–induced psoriasis-like skin lesions in BALB/c mice via suppression of inflammation response. BIOMEDICINE & PHARMACOTHERAPY, 2020 (PubMed: 32920513) [IF=7.5]

Application: WB    Species: Mice    Sample: RAW264.7 cells

Fig. 7. Anti-inflammatory effects and suppressive effects of luteolin on the NF-κB signaling pathway in RAW264.7 cells. A). NO levels in the cell culture media of Raw264.7 cells were determined using a Griess assay. B–E). Western blot analysis of iNOS, COX-2, NF-κB and p-NF-κB expression. These assays were performed in three in dependent experiments. ANOVA followed by Bonferroni’s multiple comparison tests was used. (*) p < 0.05, (***) p < 0.001 and (****) p < 0.0001 versus control group treated with vehicle; (##) p < 0.01, (###) p < 0.001 and (####) p < 0.0001 versus model group.

9). Protective effects of 4-geranyloxy-2,6-dihydroxybenzophenonel on DSS-induced ulcerative colitis in mice via regulation of cAMP/PKA/CREB and NF-κB signaling pathways. Phytotherapy Research, 2023 (PubMed: 36428266) [IF=7.2]

10). Design, synthesis and bioactivity study of N-salicyloyl tryptamine derivatives as multifunctional agents for the treatment of neuroinflammation. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020 (PubMed: 32182488) [IF=6.7]

Application: WB    Species: Mouse    Sample: BV2 and C6 cells

Fig. 2. Effects of compounds on protein expressions of iNOS, COX-2 in LPS-induced BV2 cell lines (A) and effects of compounds on protein expressions of iNOS in LPS-induced C6 cell lines (B). BV2 cell lines were exposed to the indicated compounds at concentrations of 10, 20 and 40 mM for 24 h in the presence of LPS (1 mg/mL). C6 cell lines were exposed to the indicated compounds at concentrations of 10, 20 and 40 mM for 24 h in the presence of LPS (10 mg/mL). The expression of iNOS and COX-2 was assayed and calculated by image J. Each error bar represents the mean ± SD of three independent experiments. #, p < 0.05 versus the control group; ##, p < 0.01 versus the control group; ###, p < 0.001 versus the control group. *, p < 0.05, **, p < 0.01 when compared to the LPS-treated cells. All data are the mean ± SD of at least three independent experiments.

Load more

Restrictive clause


Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.